These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 22178727)
1. Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice. Brewoo JN; Kinney RM; Powell TD; Arguello JJ; Silengo SJ; Partidos CD; Huang CY; Stinchcomb DT; Osorio JE Vaccine; 2012 Feb; 30(8):1513-20. PubMed ID: 22178727 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques. Osorio JE; Brewoo JN; Silengo SJ; Arguello J; Moldovan IR; Tary-Lehmann M; Powell TD; Livengood JA; Kinney RM; Huang CY; Stinchcomb DT Am J Trop Med Hyg; 2011 Jun; 84(6):978-87. PubMed ID: 21633037 [TBL] [Abstract][Full Text] [Related]
3. Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice. Fuchs J; Chu H; O'Day P; Pyles R; Bourne N; Das SC; Milligan GN; Barrett AD; Partidos CD; Osorio JE Vaccine; 2014 Nov; 32(48):6537-43. PubMed ID: 25239488 [TBL] [Abstract][Full Text] [Related]
4. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Osorio JE; Huang CY; Kinney RM; Stinchcomb DT Vaccine; 2011 Sep; 29(42):7251-60. PubMed ID: 21777638 [TBL] [Abstract][Full Text] [Related]
5. Development of a recombinant, chimeric tetravalent dengue vaccine candidate. Osorio JE; Partidos CD; Wallace D; Stinchcomb DT Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500 [TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Osorio JE; Velez ID; Thomson C; Lopez L; Jimenez A; Haller AA; Silengo S; Scott J; Boroughs KL; Stovall JL; Luy BE; Arguello J; Beatty ME; Santangelo J; Gordon GS; Huang CY; Stinchcomb DT Lancet Infect Dis; 2014 Sep; 14(9):830-8. PubMed ID: 25087476 [TBL] [Abstract][Full Text] [Related]
7. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Osorio JE; Wallace D; Stinchcomb DT Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182 [TBL] [Abstract][Full Text] [Related]
8. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883 [TBL] [Abstract][Full Text] [Related]
9. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine. Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922 [TBL] [Abstract][Full Text] [Related]
10. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models. Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997 [TBL] [Abstract][Full Text] [Related]
11. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens. Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114 [TBL] [Abstract][Full Text] [Related]
13. Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates. Govindarajan D; Meschino S; Guan L; Clements DE; ter Meulen JH; Casimiro DR; Coller BA; Bett AJ Vaccine; 2015 Aug; 33(33):4105-16. PubMed ID: 26144900 [TBL] [Abstract][Full Text] [Related]
14. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults. Kirkpatrick BD; Durbin AP; Pierce KK; Carmolli MP; Tibery CM; Grier PL; Hynes N; Diehl SA; Elwood D; Jarvis AP; Sabundayo BP; Lyon CE; Larsson CJ; Jo M; Lovchik JM; Luke CJ; Walsh MC; Fraser EA; Subbarao K; Whitehead SS J Infect Dis; 2015 Sep; 212(5):702-10. PubMed ID: 25801652 [TBL] [Abstract][Full Text] [Related]
15. Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination. Briggs CM; Smith KM; Piper A; Huitt E; Spears CJ; Quiles M; Ribeiro M; Thomas ME; Brown DT; Hernandez R J Virol; 2014 Jun; 88(12):6729-42. PubMed ID: 24696467 [TBL] [Abstract][Full Text] [Related]
17. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine. Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701 [TBL] [Abstract][Full Text] [Related]
18. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties. Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151 [TBL] [Abstract][Full Text] [Related]
19. Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype. Metz SW; Thomas A; Brackbill A; Xianwen Y; Stone M; Horvath K; Miley MJ; Luft C; DeSimone JM; Tian S; de Silva AM PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006793. PubMed ID: 30248097 [TBL] [Abstract][Full Text] [Related]
20. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice. Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]